Anaveon appoints Dieter Weinand as Chair of its Board of Directors
30 Julio 2024 - 1:00AM
Anaveon, a clinical stage, immuno-oncology company, today announced
the appointment of Dieter Weinand, former Chair and CEO of Bayer
Pharmaceuticals, as Chair of its Board of Directors. Martin Murphy,
who served as Chair since 2019, has stepped down from the Board.
“We are pleased to welcome Dieter to Anaveon’s
Board. He brings a wealth of strategic and operational experience
to Anaveon as we look to advance our lead solid tumor programs
through clinical studies and expand our pipeline with novel drug
candidates,” said Andreas Katopodis, Chief Executive
Officer at Anaveon. “We are greatly indebted to Martin for
his contributions and guidance as Chair since the founding of the
Company and wish him every success in the future.”
“I am very pleased to become Chair of the Board for
Anaveon, a company I believe has the potential to make a
significant difference in the lives of patients,” said
Dieter Weinand. “I look forward to working together with
Andreas and the Anaveon team to advance the company through its
next stages of growth and to achieve its strategic business and
pipeline objectives.”
Dieter Weinand is an experienced business leader in
the pharmaceutical industry and is the former Chair and CEO of
Bayer Pharmaceuticals. During a career stretching back over 30
years he has held various responsibilities in general management,
commercial, operational and strategic leadership roles, leading
business operations in the Asia-Pacific region, Europe, the Middle
East, Africa, Latin America and the United States for companies
including Bayer, Pfizer, Bristol-Myers Squibb, and Sanofi. He has
also led the development, launch, and commercialization of products
in various therapeutic areas, including cardiovascular diseases,
oncology, dermatology, immunology, and respiratory and inflammatory
diseases. He is currently Chair of the Board of Replimune (REPL),
Umoja, and Inspirna, and Executive Chair of the Board of Mnemo
Therapeutics as well as serving on the Board of Meliora
Therapeutics. He earned an M.S. in pharmacology and toxicology from
Long Island University, New York, and a B.A. in biology from
Concordia College, New York.
Media contact:JW Communications
Julia Wilson Email: julia.wilson@anaveon.comTel: +44 (0)7818
430877
About Anaveon:Anaveon is a
biotechnology company located in Basel, Switzerland. Using our
immunological knowledge and expertise in protein engineering, we
develop medicines to deliver meaningful benefits to cancer
patients. Our lead compounds, ANV419 and ANV600, are currently in
clinical trials in solid tumors.
Find out more at >
anaveon.com